In connection with the development of mRNA-based vaccines against Corona, lipid nanoparticles (LNPs) have shown to be a suitable delivery form. LNPs encapsulate and protect the delicate active ingredient and allow its transport to the target cells in the human body. This will be the first large-scale use of mRNA and lipid nanoparticles in vaccination history. KNAUER, the Berlin based manufacturer of high-tech laboratory instruments mostly known for its liquid chromatography systems, also supplies production equipment for pharmaceutical lipid nanoparticles. This development was made possible by combining the company’s expertise in high pressure dosing and in laboratory systems engineering.  New and promising developments in medicine make pharmaceuticals and their active…